Background: Pulmonary Arterial Hypertension (PAH) is a severe and progressive disease
of pulmonary arterioles. This pathology is characterized by elevation of the pulmonary vascular
resistance and pulmonary arterial pressure, leading to right heart failure and death. Studies have
demonstrated that resveratrol possesses a protective effect on the mechanisms related to the genesis
of the PAH-induced by different models.
Objective: This study aimed to investigate the dose-related effects of resveratrol in different models
of pulmonary arterial hypertension.
Methods: To identify eligible papers, we performed a systematic literature search on Scielo, Pub-
Med, and Scholar Google. The research was limited to articles written in English in the last 10
years. We used the following descriptors to search: Pulmonary Arterial Hypertension and Resveratrol,
OR Resveratrol, and Animal models of Pulmonary Arterial Hypertension, OR Resveratrol, and
in vitro models of Pulmonary Arterial Hypertension.
Results: 1724 studies were identified through the descriptors used, fifty-five studies with different
models of pulmonary arterial hypertension were selected for the full review, forty-four were excluded
after application of exclusion and inclusion criteria, totalizing eleven studies included in this
Conclusion: The results showed that resveratrol, at low and high doses, protects in a dosedependent
manner against the development of PAH induced through monocrotaline, normoxia and
hypoxia models. In addition to having chemopreventive, anti-inflammatory, antioxidant and antiproliferative
properties. In the case of PAH-related myocardial injury, resveratrol protects cells
from apoptosis, thus working as an antiapoptotic agent.